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The prevalence and economic burden of coronary artery disease are high. New noninvasive diagnostic
imaging methods have evolved in recent decades, including coronary computed tomography angiog-
raphy and cardiac magnetic resonance angiography. Investigations into functional ischemic parameters
have also been added to anatomical imaging to improve diagnostic performance, including the fractional
ﬂow reserve calculated from contrast computed tomography, perfusion computed tomography, perfusion
cardiac magnetic resonance imaging, a combination of coronary computed tomography angiography
with myocardial perfusion scintigraphy and the myocardial ﬂow reserve calculated from perfusion
positron emission tomography. In this article, we will discuss progress in noninvasive imaging modalities
for the diagnosis of coronary artery disease and trends for the future.
Copyright  2013, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
Despite advances in diagnosis, prevention and treatment, cor-
onary artery disease (CAD) is still a prevalent disease worldwide.
Data from the National Health and Nutrition Examination Survey
2007e2010 showed that an estimated 15.4 million Americans 20
years of age have CAD [1]. CAD causes a large economic burden,
which is growing with its increasing prevalence.
The traditional noninvasive imaging modality for CAD is
myocardial perfusion scintigraphy (MPS), which can assess physi-
ological evidence of signiﬁcant coronary artery stenosis. Emerging
noninvasive modalities include coronary computed tomography
angiography (CCTA) and cardiac magnetic resonance imaging
(CMRI) angiography, which provide anatomical evidence of CAD.
However, the anatomical information lacks hemodynamic infor-
mation for CAD and the literature has demonstrated that anatom-
ical lesions do not correlate with the ischemic indicator, the
fractional ﬂow reserve (FFR) [2]. During the past few years, the
trend has changed to incorporate anatomical images withMedicine, Buddhist Tzu Chi
ualien, Taiwan. Tel.: þ886 3
H. Chen).
ddhist Compassion Relief Tzu Chifunctional parameters to make up for the disadvantages of
anatomical imaging modalities. In this review, we discuss the
recent evolution of noninvasive imaging modalities for the diag-
nosis of CAD, and also the recent usage of positron emission to-
mography (PET) in CAD.
The traditional noninvasive imaging approach to detecting CAD
is radionuclide myocardial perfusion imaging (Fig. 1). This tool
provides pathophysiological evidence of CAD. However, sometimes
there are nondiagnostic or conﬂicting situations that require cor-
onary angiography (CA) for anatomical assessment. Unfortunately,
CA is invasive and expensive, and may result in severe complica-
tions such as coronary artery dissection. Thus, noninvasive
anatomical imaging modalities were developed. CMRI angiography
was ﬁrst described by Manning et al in 1993 and CCTA was ﬁrst
described by Moshage et al in 1995 [3,4].2. Diagnostic performance of CCTA and CMRI angiography
CCTA demonstrates excellent coronary artery anatomy (Fig. 2)
and many single-center trials have investigated its diagnostic per-
formance. In a systemic review of 23 studies with a total of 2045
patients with suspected or known CAD, Stein et al compared 64-
slice CCTA with invasive CA in the diagnosis of CAD [5]. The
sensitivity for detecting signiﬁcant stenosis (50%) in patient-Foundation. Published by Elsevier Taiwan LLC. All rights reserved.
Fig. 1. Myocardial perfusion scintigraphy shows myocardial ischemia at the apical
segment of the left ventricle.
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patient-based evaluations was 88%. The positive predictive value
(PPV) for patient-based evaluations varied widely according to
vascular site (69e93%), and the negative predictive value (NPV)was
96e100%. Another meta-analysis investigating 28 studies including
1286 patients yielded similar results [6]. The per-patient pooled
sensitivity, speciﬁcity, PPV and NPV were 99%, 89%, 93% and 100%,
respectively. The high NPV has prompted the use of CCTA to rule out
CAD.
Multicenter studies, however, have had more variable results.
Four multicenter studies investigating the use of CCTA in diag-
nosing CAD, the Assessment by Coronary Computed Tomographic
Angiography of Individuals Undergoing Invasive Coronary Angi-
ography (ACCURACY), The Coronary Artery Evaluation Using
64-Row Multidetector Computed Tomography Angiography (CORE
64), Meijboom et al and Ontario Multi-detector Computed Tomo-
graphic Coronary Angiography Study (OMCAS) studies, showedFig. 2. (A) A coronary computed tomography angiography reformatted image reveals stenosi
in another patient shows absence of the right coronary artery, indicating complete occlusiowidely varying diagnostic performance with sensitivities of 81.3%
(OMCAS) to 99% (Meijboom et al) and speciﬁcities of 64% (Meij-
boom et al) to 93.3% (OMCAS). The PPV also varied widely from 64%
(ACCURACY) to 91.6% (OMCAS) and the NPV from 83% (CORE 64) to
99% (ACCURACY) [7e10]. The varied results might be related to
different prevalences of CAD among the patient groups in the
different trials. With a lower CAD prevalence (ACCURACY trial), the
diagnostic performance was more similar to those in single-center
trials. However, the higher CAD prevalence in other multicenter
trials resulted in a more variable diagnostic performance. This may
also indicate that more multicenter trials are needed for better
documentation of the diagnostic performance of CCTA [11].
Nevertheless, to sum up the results from single-center and multi-
center studies, the NPV of CCTA is still valuable for low-risk patients
to rule out CAD.
Two multicenter studies of CMRI are available. In the earlier
study, which included 109 patients with comparison to invasive CA,
CMRI had an overall sensitivity and speciﬁcity of 93% and 42%
respectively for detecting 50% coronary artery stenosis [12]. The
more recent multicenter study of 138 patients yielded a patient-
based sensitivity, speciﬁcity, PPV and NPV of 88%, 72%, 71% and
88%, respectively [13]. The diagnostic performance of CMRI angi-
ography was inferior to that of CCTA.3. Downstream results comparison with MPS
The downstream results including patients’ health outcomes,
subsequent procedures and cost-effectiveness of CCTA compared
with MPS, have been less investigated. Min et al demonstrated that
patients without known CAD initially evaluated by CCTA had lower
subsequent costs (around 30%) compared with patients initially
evaluated by MPS. Although healthcare expenditures were lower,
the health outcomes were similar, including CAD-related hospital-
ization, myocardial infarction, onset of angina, and CAD outpatient
visits [14]. A more recent prospective study of 180 patients pre-
senting with chest pain and suspected CAD who were followed-up
for 55 days showed similar results [15]. In contrast, Shreibati et al’s
retrospective study which included 282,830 patients showed that
total spending and CAD-related spending were signiﬁcantly higher
in the CCTA group than theMPS group. Therewasmore noninvasive
and invasive cardiac testing andmore revascularization in the CCTA
group [16]. This can be explained by a higher prevalence of CAD ins in the right coronary artery (arrow). (B) Coronary computed tomography angiography
n of the right coronary artery.
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in populations with a high pretest likelihood of CAD [11]. In this
group, patients with anatomical stenosis on CCTA without signiﬁ-
cant ischemia may undergo unnecessary revascularization.
4. Limitations of CCTA and CMRI angiography
Although the NPV of CCTA is high, this modality has several
limitations. A rapid heart rate, irregular rhythm and severe coro-
nary calciﬁcation interfere with image quality [17,18]. This was
demonstrated in the ACCURACY trial, where the speciﬁcity fell from
83% to 53% in patients with an Agatston score greater than 400
units [7]. In addition, narrow coronary arteries (diameter<1.5 mm)
cannot be analyzed and have been excluded from most trials of
CCTA. Small-artery CAD is often undiagnosed.
Intracoronary metal stents, which produce metal artifact in
CCTA and image distortion in CMRI angiography, mask nearby
coronary lesions. Also, many implants such as cardiac pacemakers
and deﬁbrillators are contraindicated in CMRI examinations [19].
Recent studies have demonstrated that stenosis on angiography
does not correlate with the FFR. Meijboom et al used the FFR in
invasive coronary angiography as the reference standard to calcu-
late the correlation between ischemic indicators and anatomical
lesions. The correlation coefﬁcient of quantitative CCTA and the FFR
was e0.32; and that of quantitative invasive coronary angiography
and the FFR was e0.30 [2]. These results indicate that coronary
stenosis on angiography does not necessarily represent ischemia.
Patients may therefore be over-treated if only angiographic results
are considered. The limitations of anatomical imaging have
prompted the emergence of new functional imaging.
Recent imaging strategies have included a combination of
anatomical images with functional parameters. Examples include a
combination of CCTA with MPS (CCTA/MPS), CCTA with perfusion
computed tomography (CCTA/CTP), CCTAwith FFRCT (FFR calculated
by CCTA), and CMRI perfusion images and cardiac perfusion PET.
5. Combination of CCTA and MPS
Rispler et al evaluated the diagnostic performance of CCTA/MPS
in 56 patients, and the sensitivity, speciﬁcity, PPV and NPV of CCTA
alone for the detection of greater than 50% coronary stenosis were
96%, 63%, 31% and 99%, respectively, with a positive likelihood ratioFig. 3. (A) Left anterior descending artery stenosis on coronary computed tomography ang
mography angiography is <0.80 (arrowhead) [26].of 2.6 [20]. The same measures for CCTA/MPS were 96%, 95%, 77%
and 99%, respectively, with a positive likelihood ratio of 19.2. This
suggests that with a combination of MPS, speciﬁcity can be
improved. However, the speciﬁcity of CCTA alone in this study was
much lower than that in previously published data [5,6]. A possible
explanation for this is that CCTA was performed by 16-slice
computed tomography, which may provide poor quality images
compared with 64-slice computed tomography. More recently, Sato
et al used 64-slice computed tomography and the diagnostic per-
formance was better [21].
6. CCTA/CTP
CCTA is limited to anatomical evaluation and cardiac perfusion
computed tomography has been investigated to provide functional
information. A recent systemic review and meta-analysis evaluated
the diagnostic performance of vasodilator stress cardiac computed
tomography perfusion imaging in CAD [22]. If only vasodilator
stress perfusion imaging was used, the speciﬁcity was only 59%
when invasive coronary angiography was used as a reference. The
results were unfavorable compared with MPS (which has a speci-
ﬁcity of 76% based on a recent systemic review and meta-analysis)
[23]. However, CCTA/CTP showed excellent diagnostic performance
when combined with invasive coronary angiography using MPS as
a reference; the sensitivity, speciﬁcity, PPV and NPV were 86%, 92%,
92% and 85%, respectively. A similar diagnostic performance was
obtained for CCTA/CTP when invasive coronary angiography with
the FFR was used as a reference; the pooled sensitivity, speciﬁcity,
PPV and NPV in the two studies were 81%, 93%, 87% and 88%,
respectively [22]. Although the results of CCTA/CTP seemed
promising, the sample sizes in the studies were relatively small,
with only 26 patients in the study comparing CCTA/CTP to a com-
bination of invasive coronary angiography with MPS, and a total of
75 patients in the comparison of CCTA/CTP to invasive coronary
angiography with the FFR. Thus, more trials are needed for further
validation of the usage of CCTA/CTP in diagnosing CAD.
7. CCTA with FFRCT
Recently, evidence has shown that CCTA/FFRCT has good per-
formance in diagnosing CAD. The Diagnosis of Ischemia-Causing
Stenoses Obtained Via Noninvasive Fractional Flow Reserveiography in the study by Min et al. (B) The FFR calculated by coronary computed to-
Table 1
Comparison of diagnostic performance between cardiac magnetic resonance imaging (CMRI) and myocardial perfusion scintigraphy (MPS).
Reference Patients Prevalence
of CAD
Comparison Sensitivity
(95% CI)
Speciﬁcity
(95% CI)
PPV (95% CI) NPV (95% CI) AUC (95% CI)
MR-IMPACT II
[33,34]
515 (60  10 y,
73% male)
49% CMRI vs. MPS 75 (68e82) vs.
59 (49e69)
59 (51e67) vs.
72 (58e86)
70 (65e75) vs.
73 (65e81)
65 (60e70) vs.
60 (57e53)
0.75  0.02 vs.
0.65  0.03
CE-MARC [35] 752 (60  10 y,
63% male)
39% CMRI vs. MPS 87 (82e90) vs.
67 (60e72)
83 (80e87) vs.
83 (79e86)
77 (72e82) vs.
71 (65e77)
91 (87e93) vs.
79 (75e83)
0.84  0.03 vs.
0.69  0.04
AUC ¼ area under the curve; CAD ¼ coronary artery disease; CI ¼ conﬁdence interval; NPV ¼ negative predictive value; PPV ¼ positive predictive value.
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CCTA/FFRCT with the reference of invasive CA and the FFR in 103
patients. The per-segment based sensitivity, speciﬁcity, PPV, NPV
and accuracy were 87.9%, 82.2%, 73.9%, 92.2% and 84.3%, respec-
tively, with an area under the receiver-operator characteristics
curve (AUC) of 0.90. The diagnostic performance greatly exceeded
that of CCTA alone (same statistical measures 91.4%, 39.6%, 46.5%,
88.9% and 58.5%, respectively). The study also demonstrated a
good correlation (r ¼ 0.717) between the FFRCT and FFR [24,25]. A
more recent and larger trial by Min et al included 252 patients for
per-patient based analysis using invasive CA and the FFR as a
reference. The sensitivity, speciﬁcity, PPV, NPV and accuracy for
CCTA/FFRCT were 90%, 54%, 67%, 84% and 73%, respectively, with
an AUC of 0.81; the results for CCTA only were 84%, 42%, 61%, 72%
and 64%, with an AUC of 0.68 (Fig. 3) [26]. Although the diagnostic
performance was not as impressive as in the DISCOVER-FLOW
study, it consistently outperformed CCTA alone and it seems
promising that the functional ischemic indicator, the FFR, can be
measured noninvasively.8. CMRI perfusion images
Two large trials have compared the diagnostic performance of
CMRI and MPS in CAD: the Magnetic Resonance Imaging for
Myocardial Perfusion Assessment in Coronary Artery Disease Trial
(MR IMPACT II) [27,28] and The Clinical Evaluation of MAgnetic
Resonance imaging in Coronary heart disease study (CE-MARC)
(Table 1) [29].
In MR-IMPACT II, the sensitivity of CMRI was better than that of
MPS (75% vs. 59%); however, the speciﬁcity of MPS (72%) was betterFig. 4. In the CE-MARC trial, late gadolinium-enhanced cardiac magnetic resonance
imaging shows a transmural inferior myocardial infarct (arrow) [29].than that of CMRI (59%). The calculated positive likelihood ratios of
CMRI and MPS were 1.83 and 2.11, respectively. The MR-IMPACT II
showed that the AUC of CMRI signiﬁcantly outperformed that of
both gated and non-gated MPS.
The CE-MARC study (Fig. 4) showed that the sensitivity [29],
speciﬁcity, PPV, NPV and AUC were all better than MPS (Table 1),
indicating that the diagnostic performance of CMRI is better than
MPS.
The sensitivity of MPS in the two studies, however, was unex-
pectedly low and was inconsistent with previously reported results
from multiple single-center and multicenter trials [23,30]. Flotats
et al and Schaefer et al also demonstrated that the difference may
be due to the technical limitations of single-photon emission
computed tomography (SPECT) [31,32].
Another randomized controlled trial, the Cost-Effectiveness of
Functional Cardiac Testing trial (CECaT trial), evaluated different
functional cardiac tests in the diagnosis andmanagement of CAD in
comparison with angiography in 898 patients. The results showed
that MPS was as useful as angiography in identifying patients who
should undergo revascularization and the additional cost was not
signiﬁcant. On the contrary, CMRI had the largest number of test
failures [33]. Therefore, as it is a new technique, CMRI still requires
further work and more multicenter studies before adoption in
routine clinical practice.9. Cardiac perfusion PET
Although not used widely in clinical practice, cardiac PET
perfusion imaging offers technical beneﬁts over MPS with SPECT. A
recent meta-analysis using invasive coronary angiography as a
reference standard demonstrated that the sensitivities of cardiac
perfusion PET and SPECT MPS were 92.6% (95% conﬁdence interval:
88.3e95.5%) and 88.3% (95% conﬁdence interval: 86.4e90.0%) with
p ¼ 0.035. No signiﬁcant difference in speciﬁcity was noted be-
tween the two image modalities [34]. PET offers improved imageFig. 5. An apical perfusion defect is demonstrated by perfusion radiotracer (13N-
ammonia) whereas 18F-ﬂuorodeoxyglucose positron emission tomography shows no
decrease in glucose metabolism. This typical perfusionemetabolism mismatch in-
dicates viable myocardium under ischemia [37].
Table 2
Limitations and advantages of existing noninvasive diagnostic modalities.
Image tool Limitation Advantage
Angiography-based
images
CCTA Tachycardia, irregular rhythm, coronary calciﬁcation,
diameter <1.5 mm, contrast nephropathy or allergy,
lack functional parameter
The procedure is fast, good spatial resolution,
high NPV in low risk patients
CCTA/FFRCT Same as above except the functional parameter The procedure is fast, good spatial resolution,
provides a functional parameter to CCTA
Perfusion images CCTA/MPS Radiation hazards Provides a functional parameter to CCTA
CCTA/CTP Similar to CCTA, except the limitation of vascular
diameter and functional parameter
The procedure is fast, good spatial resolution,
provides a functional parameter to CCTA
CMRI Metal implants, irregular rhythm or breath,
technology insufﬁciency or operator inexperience,
nephrogenic systemic ﬁbrosis
No ionizing radiation, delayed enhanced image
can assess viability
PET (Perfusion/MFR
and metabolism)
Expensive, less accessible, lack of anatomical
information
Better diagnostic performance than SPECT,
MFR improves the sensitivity for balanced ischemia,
can assess viability, no contrast-related adverse
effects, rhythm or breath is not a concern
CCTA ¼ coronary computed tomography angiography; CMRI ¼ cardiac magnetic resonance imaging; CTP ¼ perfusion computed tomography; FFRCT ¼ fractional ﬂow reserve
measured by computed tomography; MFR ¼myocardial ﬂow reserve; MPS ¼ myocardial perfusion scintigraphy; NPV ¼ negative predictive value; PET ¼ positron emission
tomography.
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agreement compared with SPECT [35]. However, PET perfusion
imaging has poor sensitivity in detecting balanced myocardial
ischemia. This limitation may be overcome by the use of the
myocardial ﬂow reserve (MFR) [36]. Fiechter et al assessed the
diagnostic performance of N-13 ammonia perfusion PET with MFR
in 73 patients using invasive coronary angiography as a standard of
reference. When the cutoff was less than 2.0 for the global MFR, the
sensitivity, speciﬁcity, PPV, NPV and accuracy of perfusion PET/MFR
were 96%, 80%, 93%, 89% and 92%, respectively. The same results for
perfusion PET images were only 79%, 80%, 91%, 59%, and 79%,
respectively. The sensitivity, NPV and accuracy were signiﬁcantly
improved (p < 0.05) when the MFR was used [36]. This ﬁnding
indicates that adding MFR can compensate for limitations in diag-
nosing balanced myocardial ischemia.
Another merit of PET in evaluating CAD is the use of F-18 ﬂuo-
rodeoxyglucose PET in evaluating myocardial viability (Fig. 5) [37].
Although there are other noninvasive modalities capable of
assessing myocardial viability, such as delayed contrast-enhancedFig. 6. Diagnostic algorithm for non-invasive imaging modalities. Note that for low-risk pat
performed simultaneously. (CAD ¼ coronary artery disease; CMRI ¼ cardiac magnetic reson
tomography angiography; CTP ¼ perfusion computed tomography; FFRCT ¼ fractional ﬂow re
emission tomography.)MRI and stress echocardiography [38], diagnosis of a hibernating
myocardium by ﬂow-metabolism mismatch cannot currently be
replaced by other examinations. Information on myocardial hiber-
nation is very important in the management of CAD because
revascularization can allow resumption of myocardial function,
while an infarcted or scarred myocardium does not beneﬁt from
this procedure.
10. The future of CAD diagnosis
Data from currently available studies show promising results in
the diagnosis of CAD with emerging noninvasive imaging modal-
ities. However, the evidence is insufﬁcient for each technique to be
used routinely in clinical practice. New technologies are being
invented, including dual-energy computed tomographic tech-
niques to evaluate the myocardial blood pool as well as newer PET
myocardial perfusion tracer ﬂurpiridaz F 18 imaging [39,40].
The current trend is to add more functional parameters to
traditional anatomical imaging to improve the accuracy andients, CCTA alone is enough according to the evidence. However, CTP and FFRCT can be
ance imaging; MPS ¼ myocardial perfusion scintigraphy; CCTA ¼ coronary computed
serve measured by computed tomography; FDG ¼ ﬂuorodeoxyglucose; PET ¼ positron
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images, although FFRCT adds functional information to CCTA, it
still cannot assess vessels narrower than 1.5 mm; perfusion images,
however, are not limited by vascular caliber. Clinicians need to be
cautious about the potential insufﬁciency of using invasive coro-
nary angiography or the FFR as a reference standard for assessing
the diagnostic performance of emerging image tools. Small vascular
stenosis may not be detected by invasive coronary angiography or
the FFR, but it can appear as a perfusion defect on perfusion images.
This then can be erroneously registered as a false-positive ﬁnding
[29]. For this reason, investigators may have to consider which tool
(or tools) should be used as a reference standard for assessing the
diagnostic performance of imaging modalities in CAD.11. Conclusion
In recent decades several new noninvasive imaging modalities
have emerged, and most studies have shown promising results.
Each of the tools has limitations and advantages over the others
(Table 2). In diagnostic performance, the high NPV for CCTA sug-
gests its use in ruling out CAD. The downstream results of CCTA in
comparison with MPS, however, have been conﬂicting. This sug-
gests that CCTA might be better than MPS only in low-risk groups.
For the other tools, data are insufﬁcient to make conclusions about
their use in comparison with MPS, the most commonly used
noninvasive diagnostic modality today. The algorithm in Fig. 6 may
help in understanding the roles of various modalities in diagnosing
CAD. With advancements in technology, the references used in
assessing diagnostic performance might become unsuitable. Anal-
ogously, the diagnosis of CAD might not be sufﬁcient with invasive
angiography only, since small vascular stenosis cannot be detected.
Finally, new noninvasive imagemodalities are emerging and the
race between different tools for CAD diagnosis continues. Newer
technologies seek better diagnostic accuracy, lower radiation dos-
ages, more functional parameters and more delicate images.
However, all efforts should eventually be examined against health
outcomes and cost-effectiveness to ascertain the beneﬁts to
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